RETA — Reata Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeLarge Cap
- $6.52bn
- $6.27bn
- $2.22m
Reata Pharma up as Guggenheim initiates coverage with 'buy' rating
U.S. STOCKS ON THE MOVE-BeiGene, Avient, Reata
Reata says no plans for FDA advisers' meeting on rare disease drug, shares up
Brief: Reata Pharmaceuticals Announces That The FDA Does Not Plan To Hold An Advisory Committee Meeting To Discuss The NDA For Omaveloxolone For Friedreich’S Ataxia
Brief: Reata Pharmaceuticals Announces Three Month Extension Of The Review Period For New Drug Application For The Treatment Of Friedreich’S Ataxia
U.S. STOCKS ON THE MOVE-Tiptree, Viatris, EV charging stocks
U.S. STOCKS ON THE MOVE-Elanco, Ceco, Monday.com
Reata Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Reata slides on FDA concerns over rare disease drug
Brief: Reata Pharmaceuticals, Inc. reports Q2 results
Brief: Reata Appoints Steven Ryder To Its Board Of Directors
Brief: Reata Pharmaceuticals Announces FDA Filing Acceptance And Priority Review Designation For NDA For Omaveloxolone For Treatment Of Patients With Friedreich's Ataxia
Reata Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Reata Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results And Provides An Update On Clinical Development Programs
Reata Pharmaceuticals Inc expected to post a loss of $2.15 a share - Earnings Preview
Reata Pharmaceuticals Inc expected to post a loss of $2.15 a share - Earnings Preview
Reata Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: Reata Pharmaceuticals, Inc. Announces Fourth Quarter And Full Year 2021 Financial Results And Provides An Update On Clinical Development Programs
Brief: Reata Pharmaceuticals Receives CRL From FDA For Potential Kidney Treatment